Matthew Taylor

Assistant Professor

  • 4415 Citations
  • 16 h-Index
20102020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 4415 Citations
  • 16 h-Index
  • 30 Article
  • 1 Comment/debate
  • 1 Review article
2020

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Naing, A., Gainor, J. F., Gelderblom, H., Forde, P. M., Butler, M. O., Lin, C. C., Sharma, S., Ochoa De Olza, M., Varga, A., Taylor, M., Schellens, J. H. M., Wu, H., Sun, H., Silva, A. P., Faris, J., Mataraza, J., Cameron, S. & Bauer, T. M., Mar 15 2020, In : Journal for immunotherapy of cancer. 8, 1, e000530.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies

Taylor, M. H., Alva, A. S., Larson, T., Szpakowski, S., Purkaystha, D., Amin, A., Karpiak, L. & Piha-Paul, S. A., Apr 1 2020, In : Oncotarget. 11, 14, p. 1235-1243 9 p.

Research output: Contribution to journalArticle

Open Access

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D. R., Horn, L., Calvo, E., Li, A., Lin, W. H., Callahan, M. K. & Spigel, D. R., Mar 2020, In : Journal of Thoracic Oncology. 15, 3, p. 426-435 10 p.

Research output: Contribution to journalArticle

Open Access
9 Scopus citations

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

Ansell, S. M., Flinn, I., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J., Feldman, A., Hawthorne, T. R., Rawls, T., Keler, T. & Yellin, M. J., May 12 2020, In : Blood Advances. 4, 9, p. 1917-1926 10 p.

Research output: Contribution to journalArticle

Open Access
2019

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for immunotherapy of cancer. 7, 1, 12.

Research output: Contribution to journalArticle

8 Scopus citations

Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)

Berry, S., Giraldo, N., Nguyen, P., Green, B., Xu, H., Ogurtsova, A., Soni, A., Succaria, F., Wang, D., Roberts, C., Stein, J., Engle, E., Pardoll, D., Anders, R., Cottrell, T., Taube, J. M., Tran, B., Voskoboynik, M., Kuo, J., Bang, Y. L. & 72 others, Chung, H. C., Ahn, M. J., Kim, S. W., Perera, A., Freeman, D., Achour, I., Faggioni, R., Xiao, F., Ferte, C., Lemech, C., Meric-Bernstam, F., Werner, T., Hodi, S., Messersmith, W., Lewis, N., Talluto, C., Dostalek, M., Tao, A., McWhirter, S., Trujillo, D., Luke, J., Xu, C., Bomarelli, B., Qi, J., Qin, G., Yu, H., Jenkins, M., Lo, K. M., Halle, J. P., Lan, Y., Taylor, M., Vogelzang, N., Cohn, A., Stepan, D., Shumaker, R., Dutcus, C., Guo, M., Schmidt, E., Rasco, D., Brose, M., Di Simone, C., Jain, S., Richards, D., Encarnacion, C., Vogelzeng, N., Mier, J., An, J., Yang, Y. Y., Lee, W. H., Yang, J., Kim, J. K., Kim, H. G., Paek, S. H., Lee, J. W., Woo, J., Kim, J. B., Kwon, H., Lim, W., Paik, N. S., Kim, Y. K., Moon, B. I., Janku, F., Tan, D., Martin-Liberal, J., Takahashi, S., Geva, R., Gucalp, A., Chen, X., Subramanian, K., Mataraza, J., Wheler, J. & Bedard, P., Feb 13 2019, In : Journal for immunotherapy of cancer. 7, 1, 46.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial

Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., Hamilton, E. P., Annunziata, C. M., Grote, H. J., Von Heydebreck, A., Grewal, J., Chand, V. & Gulley, J. L., Mar 2019, In : JAMA Oncology. 5, 3, p. 393-401 9 p.

Research output: Contribution to journalArticle

32 Scopus citations

Efficacy and Safety of Avelumab Treatment in Patients with Advanced Unresectable Mesothelioma: Phase 1b Results from the JAVELIN Solid Tumor Trial

Hassan, R., Thomas, A., Nemunaitis, J. J., Patel, M. R., Bennouna, J., Chen, F. L., Delord, J. P., Dowlati, A., Kochuparambil, S. T., Taylor, M. H., Powderly, J. D., Vaishampayan, U. N., Verschraegen, C., Grote, H. J., Von Heydebreck, A., Chin, K. & Gulley, J. L., Mar 2019, In : JAMA Oncology. 5, 3, p. 351-357 7 p.

Research output: Contribution to journalArticle

12 Scopus citations

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: A phase 2, open-label, single-arm study

Piha-Paul, S. A., Taylor, M. H., Spitz, D., Schwartzberg, L., Beck, J. T., Bauer, T. M., Meric-Bernstam, F., Purkayastha, D., Karpiak, L., Szpakowski, S. & Braiteh, F., Jan 1 2019, In : Oncotarget. 10, 60, p. 6526-6535 10 p.

Research output: Contribution to journalArticle

Larotrectinib in adult patients with solid tumours: A multi-centre, open-label, phase i dose-escalation study

Hong, D. S., Bauer, T. M., Lee, J. J., Dowlati, A., Brose, M. S., Farago, A. F., Taylor, M., Shaw, A. T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B. B., Ebata, K., Cruickshank, S., Cox, M. C., Burris, H. A. & Doebele, R. C., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 325-331 7 p.

Research output: Contribution to journalArticle

Open Access
25 Scopus citations

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., Schmidt, E. V., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C. & Taylor, M., May 2019, In : The Lancet Oncology. 20, 5, p. 711-718 8 p.

Research output: Contribution to journalArticle

51 Scopus citations
2018

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K. W., Taylor, M., Schöffski, P., Wang, D., Ravaud, A., Gelb, A. B., Xiong, J., Rosen, G., Gulley, J. L. & Apolo, A. B., Jan 2018, In : The Lancet Oncology. 19, 1, p. 51-64 14 p.

Research output: Contribution to journalArticle

163 Scopus citations

Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients with Metastatic Melanoma

Murphy, B., Walker, J., Bassale, S., Monaco, D., Jaboin, J., Ciporen, J., Taylor, M. & Dai Kubicky, C., Jan 1 2018, (Accepted/In press) In : American Journal of Clinical Oncology: Cancer Clinical Trials.

Research output: Contribution to journalArticle

7 Scopus citations

Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children

Drilon, A., Laetsch, T. W., Kummar, S., Dubois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., Feb 22 2018, In : New England Journal of Medicine. 378, 8, p. 731-739 9 p.

Research output: Contribution to journalArticle

501 Scopus citations

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Gambacorti-Passerini, C., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., Horibe, K., Ahn, J. S., Beck, J. T., Edenfield, W. J., Shi, Y., Taylor, M., Tamura, K., Van Tine, B. A., Wu, S. J., Paolini, J., Selaru, P. & Kim, T. M., May 2018, In : American Journal of Hematology. 93, 5, p. 607-614 8 p.

Research output: Contribution to journalArticle

16 Scopus citations

Precision targeted therapy with BLU-667 for RET-driven cancers

Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., Wilson, K. J., Dipietro, L., Fleming, P., Palmer, M., Hu, M. I., Wirth, L., Brose, M. S., Ou, S. H. I., Taylor, M., Garralda, E. & 5 others, Miller, S., Wolf, B., Lengauer, C., Guzi, T. & Evans, E. K., Jul 2018, In : Cancer discovery. 8, 7, p. 836-849 14 p.

Research output: Contribution to journalArticle

75 Scopus citations

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Kelly, K., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., May 1 2018, In : Cancer. 124, 9, p. 2010-2017 8 p.

Research output: Contribution to journalArticle

34 Scopus citations

Signature program: A platform of basket trials

Slosberg, E. D., Kang, B. P., Peguero, J., Taylor, M., Bauer, T. M., Berry, D. A., Braiteh, F., Spira, A., Meric-Bernstam, F., Stein, S., Piha-Paul, S. A. & Salvado, A., Apr 20 2018, In : Oncotarget. 9, 30, p. 21383-21395 13 p.

Research output: Contribution to journalArticle

19 Scopus citations
2017

Academic cancer center phase i program development

Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P., Apr 2017, In : Oncologist. 22, 4, p. 369-374 6 p.

Research output: Contribution to journalComment/debate

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Kiyota, N., Robinson, B., Shah, M., Hoff, A. O., Taylor, M. H., Li, D., Dutcus, C. E., Lee, E. K., Kim, S. B. & Tahara, M., Sep 2017, In : Thyroid. 27, 9, p. 1135-1141 7 p.

Research output: Contribution to journalArticle

11 Scopus citations

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study

Ott, P., Calvo, E., Sharma, P., Jaeger, D., Ascierto, P., Chau, I., Bendell, J., Peltola, K., Taylor, M., Tschaika, M., Dorange, C., Janjigian, Y. & Le, D., Jun 1 2017, In : Annals of oncology : official journal of the European Society for Medical Oncology. 28, p. iii139

Research output: Contribution to journalArticle

Open Access

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M., Northfelt, D. W., Carson, W. E., Hawthorne, T. R., Davis, T. A., Yellin, M. J., Keler, T. & Bullock, T., Jun 20 2017, In : Journal of Clinical Oncology. 35, 18, p. 2028-2036 9 p.

Research output: Contribution to journalArticle

47 Scopus citations
2016

Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer

Robinson, B., Schlumberger, M., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S. B., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I. & Tahara, M., Nov 2016, In : Journal of Clinical Endocrinology and Metabolism. 101, 11, p. 4103-4109 7 p.

Research output: Contribution to journalArticle

30 Scopus citations

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D. R., Salama, A. K., Taylor, M., Ott, P. A., Horak, C., Gagnier, P., Jiang, J., Wolchok, J. D. & 1 others, Postow, M. A., Nov 1 2016, In : The Lancet Oncology. 17, 11, p. 1558-1568 11 p.

Research output: Contribution to journalArticle

423 Scopus citations

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., Morse, M. A., Ascierto, P. A., Horn, L., Amin, A., Pillai, R. N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P. & 4 others, Harbison, C. T., Lin, C. S., Christensen, O. & Calvo, E., Jul 1 2016, In : The Lancet Oncology. 17, 7, p. 883-895 13 p.

Research output: Contribution to journalArticle

506 Scopus citations

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Graff, J., Higano, C. S., Hahn, N. M., Taylor, M., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J. & Sarantopoulos, J., Aug 15 2016, In : Cancer. 122, 16, p. 2524-2533 10 p.

Research output: Contribution to journalArticle

14 Scopus citations

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Gianoukakis, A. G., Flores, N. M., Pelletier, C. L., Forsythe, A., Wolfe, G. R. & Taylor, M. H., May 30 2016, In : Cancer Management and Research. 8, p. 67-76 10 p.

Research output: Contribution to journalArticle

3 Scopus citations
2015

Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers

Naugler, W. E., Tarlow, B. D., Fedorov, L. M., Taylor, M., Pelz, C., Li, B., Darnell, J. & Grompe, M., Sep 1 2015, In : Gastroenterology. 149, 3, p. 728e15-740.e15

Research output: Contribution to journalArticle

50 Scopus citations

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., Gianoukakis, A. G., Kiyota, N., Taylor, M. H., Kim, S. B., Krzyzanowska, M. K., Dutcus, C. E., De Las Heras, B., Zhu, J. & Sherman, S. I., Feb 12 2015, In : New England Journal of Medicine. 372, 7, p. 621-630 10 p.

Research output: Contribution to journalArticle

498 Scopus citations

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D. & 1 others, Hodi, F. S., May 21 2015, In : New England Journal of Medicine. 372, 21, p. 2006-2017 12 p.

Research output: Contribution to journalArticle

1585 Scopus citations
2014

Medical Therapy for Advanced Forms of Thyroid Cancer

Rajhbeharrysingh, U., Taylor, M. & Milas, M., Jun 2014, In : Surgical Clinics of North America. 94, 3, p. 541-571 31 p.

Research output: Contribution to journalReview article

7 Scopus citations
2010

The ploidy conveyor of mature hepatocytes as a source of genetic variation

Duncan, A. W., Taylor, M. H., Hickey, R. D., Hanlon Newell, A. E., Lenzi, M. L., Olson, S. B., Finegold, M. J. & Grompe, M., Oct 7 2010, In : Nature. 467, 7316, p. 707-710 4 p.

Research output: Contribution to journalArticle

287 Scopus citations